Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Goldman Sachs hosted a meeting with Pfizer Inc's PFE newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target of $33. When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects. With an annual R&D budget of abo ...